Tyler brings significant leadership experience developing innovative and disruptive medical technologies through his collaborations with global thought leaders. Prior to his role at Medley Therapeutics, Tyler led PreludeDx from concept to commercial launch and was responsible for building the commercial executive team before his departure to Medley Therapeutics. His contributions include setting corporate strategy, driving product development, managing strategic transactions and licensing, executing clinical trials and cultivating relationships with thought leaders. Tyler has been involved in the formation of multiple start-up companies in the cardiovascular, ophthalmic, diabetes and oncology fields through his positions at Fjord Ventures, a California based technology accelerator and venture group. Tyler holds a B.S. from Vanderbilt University in Biomedical Engineering and minor in Financial Economics. Tyler trained as an intern at MD Anderson Cancer Center in the Department of Research. He also holds an M.B.S. in Business and Bioprocessing from Keck Graduate Institute of Applied Lifesciences, a Claremont College.
